

PFIZER – MERCK alliance for Ertugliflozin – Not a better partner than Merck

<https://marketpublishers.com/r/P23B6DA663DEN.html>

Date: April 2013

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: P23B6DA663DEN

Abstracts

Merck-Pfizer deal for SGLT2 inhibitor - Ertugliflozin is positive and we see Merck as an ideal partner. The fixed dose combination of Ertugliflozin and Januvia should allow Ertugliflozin a head start in an otherwise competitive market. The odds of approval are difficult to predict as we have not seen clinical data as yet, but as such SGLT2 remains a risky class and we will have to wait and watch to see if Ertugliflozin is able to emerge clean of safety issues and pave through the high regulatory hurdles for anti-diabetes drug. We currently do not forecast sales from this franchise.

I would like to order

Product name: PFIZER – MERCK alliance for Ertugliflozin – Not a better partner than Merck

Product link: <https://marketpublishers.com/r/P23B6DA663DEN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P23B6DA663DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970